Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ABSI Absci Corp
3.050-0.310-9.23%
Close
02/08 16:00 ET
3.060+0.010+0.33%
Pre Mkt Price 02/09 08:11 ET
High
3.539
Open
3.320
Turnover
2.74M
Low
3.010
Pre Close
3.360
Volume
840.93K
Pre-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
St. John’s Cancer Institute Partners With Absci to Expedite Development of Cancer Therapies
Absci's generative AI and wet lab capabilities combined with St. John's Cancer Institute's molecular database of cancer patient specimens will accelerate the development of immunotherapies. VANCOUVER,
Press Release: Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation
Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation In silico antibody design expert Dr. Victor Greiff, synthetic biology pioneer Dr. Timothy Lu, and translational medic
Financial Comparison: Affinity Energy and Health (OTCMKTS:ALGXY) Vs. Absci (NASDAQ:ABSI)
Affinity Energy and Health (OTCMKTS:ALGXY – Get Rating) and Absci (NASDAQ:ABSI – Get Rating) are both medical companies, but which is the better investment? We will compare the two businesses based o
Absci (NASDAQ:ABSI) Shares Up 1%
Shares of Absci Co. (NASDAQ:ABSI – Get Rating) traded up 1% during mid-day trading on Tuesday . The company traded as high as $3.25 and last traded at $3.12. 466,859 shares were traded during tradin
Absci (NASDAQ:ABSI) Trading 1% Higher
Absci Co. (NASDAQ:ABSI – Get Rating)'s share price traded up 1% during trading on Tuesday . The company traded as high as $3.25 and last traded at $3.12. 466,859 shares were traded during trading, a
MNPR and NXL Among Healthcare Movers
BLCM, NVVE and BYSI Among Mid-day Movers
Absci First to Create and Validate De Novo Antibodies With Zero-Shot Generative AI
This breakthrough unlocks the potential to accelerate time to clinic by over 50% and increase probability of success in the clinic Creating antibodies in silico with generative AI represents a major industry
Absci (NASDAQ:ABSI) Shareholders Have Endured a 76% Loss From Investing in the Stock a Year Ago
Absci to Participate in the 41st Annual J.P. Morgan Healthcare Conference
VANCOUVER, Wash. and NEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 41st Annual
Company Overview
More
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.
CEO： Mr. Sean McClain
Market： NASDAQ
Listing Date： 07/22/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet